IMPORTANCE Presence of thyroid autoantibodies in women with normal thyroid function is associated with increased risk of miscarriage. Whether levothyroxine treatment improves pregnancy outcomes among women undergoing in vitro fertilization and embryo transfer (IVF-ET) is unknown.
T hyroid hormones are important in regulating metabolism and reproductive health. Overt hypothyroidism has been associated with increased risk of spontaneous miscarriage and preterm delivery. 1 Thyroid autoimmunity, defined as presence of the thyroid autoantibodies, antithyroperoxidase antibody, or antithyroglobulin antibody, is the most common cause of hypothyroidism among women of childbearing age. 2 The prevalence of thyroid autoimmunity among women of reproductive age is 8% to 14% worldwide. 2 Women who test positive for thyroid autoantibodies have been reported to be at 2-to 3-fold higher risk of spontaneous miscarriage than those who test negative. 3, 4 However, the effect of levothyroxine on miscarriage among women whose thyroid function is intact yet who test positive for thyroid autoantibodies has been documented in limited studies with conflicting results. 5, 6 The prevalence of thyroid autoimmunity is increased among women who are infertile. 7 One of the most frequently applied treatments in infertility is in vitro fertilization and embryo transfer (IVF-ET). Several studies that examined the association between presence of thyroid autoantibodies and IVF-ET outcomes suggested that the miscarriage rate increased with their presence, thus reducing the live-birth rate. 8 It is hypothesized that there is underlying subtle hypothyroidism after controlled ovarian hyperstimulation in women with positive thyroid autoantibodies. 9 If this were the case, supplementation of levothyroxine before initiation of IVF-ET cycle may improve outcomes. However, limited studies have evaluated the effect of levothyroxine on miscarriage among women undergoing IVF-ET who tested positive for thyroid autoantibodies but had normal thyroid function. 10 The 2017 American Thyroid Association guideline concluded that "there is insufficient evidence to determine whether levothyroxine therapy improves the success of pregnancy following assisted reproductive technology in antithyroperoxidase antibody positive, euthyroid women." 11 Therefore, the Pregnancy Outcomes Study in Euthyroid Women With Thyroid Autoimmunity After Levothyroxine (POSTAL) study was conducted to evaluate whether levothyroxine treatment initiated before IVF-ET could decrease the miscarriage rate and improve the live-birth rate among women who tested positive for antithyroperoxidase antibodies but otherwise had normal thyroid function.
Methods

Trial Design and Ethical Approval
This single-center, randomized, open-label, superiority trial was approved by the Reproductive Health Ethics Committee of Peking University Third Hospital. The study protocol and statistical analysis plan are available in Supplement 1. All the eligible participants gave their written informed consent.
Recruitment
Women referred to the reproductive center for their first or second fresh IVF-ET cycle were screened for eligibility. The start date of participant enrollment was September 6, 2012 , and June 15, 2016, was the end date. To determine the causes of infertility, all women received a routine examination, including ultrasound for uterus, fallopian tubes, and ovaries and underwent laboratory assays, hysteroscopy, and hysterosalpingography. In addition, a sperm test for the partner was usually also needed. The indications for IVF-ET were oviduct obstruction, ovulation dysfunction, endometriosis, oligospermia, immune infertility, or unexplained infertility.
To be eligible, participants had to be between the ages of 23 years and 40 years and a body mass index (calculated as weight in kilograms divided by height in meters squared) of 35 or less. Women taking a thyroid hormone or antithyroid medication or who had undergone thyroid surgery or radioiodine treatment were excluded from the trial. Women were not eligible if they had 2 or more spontaneous miscarriages; had known diabetes mellitus or other endocrinologic or metabolic diseases; had tested positive for the anticardiolipin antibody, antinuclear antibody, or lupus anticoagulants; had serum alanine aminotransferase and aspartate aminotransferase levels more than 2 times the upper limit of normal; had a serum creatinine concentration of more than 1.47 mg/dL (to convert from mg/dL to μmol/L, multiply by 88.4); or were taking adjuvant treatments, such as anticoagulants, glucocorticoids, or other relevant treatments.
All women scheduled for their first or second IVF-ET cycle were tested for antithyroperoxidase antibodies, antithyroglobulin antibodies, total thyroxine, free thyroxine, thyroidstimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone, prolactin, estradiol, and testosterone by commercial kits (Siemens Healthcare Diagnostics) using a fully automatic chemiluminescence immunoassay analyzer (ADVIA Centaur XP, Siemens Healthcare Diagnostics). Serum anticardiolipin antibodies were measured by a commercial kit (Inova Diagnostics) using chemiluminescence immunoassay (Bio-Flash, Inova Diagnostics). Serum antinuclear antibodies were detected by a commercial kit (EUROIMMUN Service) using an immunofluorescent method (Olympus BX61). The immunoturbidimetry method (ACL TOP700, Instrumentation Laboratory) was used to test the silica clot time and dilute Russell viper venom time for screening of lupus anticoagulants. Women with normal thyroid function, defined as the TSH level within the reference range of 0.50 to
Key Points
Question Does levothyroxine treatment improve outcomes following in vitro fertilization and embryo transfer in women who have tested positive for thyroid autoantibodies but otherwise have normal thyroid function?
Findings In this randomized clinical trial involving 600 women undergoing in vitro fertilization and embryo transfer who tested positive for antithyroperoxidase antibodies but who had a normal thyroid function, the miscarriage rate before 28 weeks' gestation was 10.3% among women who received and 10.6% among those who did not receive levothyroxine, a nonsignificant difference.
Meaning Levothyroxine treatment did not appear to improve pregnancy outcomes among women with thyroid autoantibodies undergoing in vitro fertilization and embryo transfer.
mIU/L
12 but tested positive for antithyroperoxidase antibody (≥60 IU/mL) with or without positive antithyroglobulin antibody (≥60 IU/mL) were potentially eligible for the study.
Randomization, Intervention, and Follow-up
Eligible women were informed about the study by one of the investigators. Thereafter, participants were randomized to receive either the intervention (levothyroxine treatment) or the blank control (no levothyroxine treatment). Randomization was performed by an independent data manager. The randomization sequence was generated in a 1:1 ratio by producing a 600 unique random-number list using EpiCalc 2000 software (http://www.brixtonhealth.com/epicalc.html), in which the even number was assigned to the intervention and the odd number to the control. Women randomized to the intervention group began levothyroxine treatment between 2 and 4 weeks before the controlled ovarian hyperstimulation and continued through the end of pregnancy. For individuals with a TSH level of 2.5 mIU/L or higher, the starting dose was 50 μg/d; for those with a TSH level of less than 2.5 mIU/L, the starting dose was 25 μg/d. For individuals with body weight less than 50 kg, the starting dose was decreased by 50%. The levothyroxine dose was titrated to keep the TSH level within 0.1 to 2.5 mIU/L in the first trimester, 0.2 to 3.0 mIU/L in the second trimester, and 0.3 to 3.0 mIU/L in the third trimester. Medication was continued if the participants achieved clinical pregnancy. During pregnancy, levothyroxine was dosed according to their TSH level monitored routinely in local hospitals. Adherence to medication was monitored by interviews during the IVF-ET cycle (the day before controlled ovarian hyperstimulation, the day of human chorionic gonadotropin (hCG) administration, and the 14th day after ET). The medication and follow-up ceased when a pregnancy did not occur during the IVF-ET cycle. Telephone follow-up calls recording levothyroxine therapy and pregnancy outcomes were performed by one of the trained physicians at 12th and 24th week of gestational age and after birth. The care of women randomized to the control group followed the same pattern as the intervention group. For participants whose TSH levels exceeded the upper limit of the normal range during pregnancy, levothyroxine was prescribed and recorded (eMethods in Supplement 2). The end date of participant follow-up was March 20, 2017.
IVF-ET Protocols
All the eligible participants underwent IVF-ET according to 1 of 4 conventional protocols. 13 In the IVF-ET long protocol, patients underwent pituitary downregulation by midluteal administration of a gonadotropin-releasing hormone (GnRH) agonist, 0.1 mg triptorelin acetate (Ipsen Pharma Biotech). In the short protocol, patients received a GnRH agonist from day 2 of their menstrual cycle onward. Controlled ovarian hyperstimulation was achieved in these patients by using either recombinant FSH (rFSH; Gonal-F, Merck Serono) or human menopausal gonadotropin (Livzon) in various flexible protocols. In the ultralong protocol, patients underwent ovarian stimulation that was induced by a rFSH protocol starting between day 28 and day 30 of their menstrual cycle after pituitary downregulation by 3.75 mg of triptorelin acetate on the first day of that cycle. In the antagonist protocol, patients who received the IVF-ET protocol started rFSH treatment on the second day of the cycle by once-daily injection. After 5 days of this treatment, the antagonist cetrorelix acetate (Merck Serono) was administered daily. The rFSH dose was adjusted according to individual ovarian response, which was assessed by daily ultrasound. The antagonist treatment continued up to, and including, the hCG day. In all treatment protocols, when at least 2 leading follicles reached 18 mm in size, ovulation was induced by between 5000 and 10 000 IU hCG (Livzon), and ovum collection was performed between 36 and 38 hours later. Oocytes were fertilized by either conventional IVF or intracytoplasmic sperm injection. One to 3 embryos were transferred on the third day of the cycle according to the Code of Practice for Assisted Reproductive Technology developed by the Ministry of Health of the People's Republic of China. Embryo transfers were performed by specified gynecologists with the same standard ET protocol. 13 The luteal phase was supported by a 60-mg progesterone (Shanghai General Pharmaceutical) injection from the day of ET to maintain lutein function through the 10th week of pregnancy. 13 
Primary and Secondary Outcomes
The primary outcome was miscarriage, defined as a pregnancy loss before 28 weeks of gestation (calculated among women who became pregnant). Miscarriage was prespecified as early miscarriage, termination within the first 12 weeks of gestation, and late miscarriage, miscarriage between 13 and 28 weeks of gestation.
14 Secondary outcomes were clinical intrauterine pregnancy and live birth. Clinical intrauterine pregnancy was defined as fetal cardiac activity 30 days after the ET procedure as observed through sonograph. 15 Live birth was defined as a delivery of a living fetus (or living fetuses) beyond 28 weeks of gestation. Exploratory analysis of the end points, twin pregnancy (confirmed by the ultrasound observation) and preterm delivery (defined as delivery of a live neonate before 37 weeks of gestation), was also performed. To assess pregnancy outcome, all pregnant women were followed up by telephone interview.
Sample-Size Calculations
Previous meta-analysis showed that the miscarriage rate among women with thyroid autoimmunity was 30% and that levothyroxine intervention could reduce the risk of miscarriage by 50%. 3 To detect a 50% decrease in miscarriage rate from Anticipating a 5% dropout rate, the total number of women required for randomization was 300 for each group.
Statistical Analysis
The statistician who conducted the analysis was blinded to group allocation. The intention-to-treat analysis was performed to evaluate the effect of levothyroxine treatment on pregnancy outcomes. The per-protocol analysis was also performed. The absolute rate difference (RD) and relative risks (RRs) with 95% CIs were estimated for the primary and secondary outcomes. The 95% CIs of absolute RDs were calculated using the Newcombe-Wilson score method.
16
Comparison between groups was performed using the independent sample t test or Pearson χ 2 test or Fisher exact test as appropriate. When continuous variables did not follow a Gaussian distribution, they were presented as median (interquartile range) and comparisons between groups were carried out using the Mann-Whitney U test. Given the complexity of the process of implantation and pregnancy, many factors might affect the pregnancy outcomes, so post hoc subgroup analyses on several known or presumable risk factors were performed. Effects of TSH levels on IVF-ET outcomes were analyzed in the subgroup analysis. According to the 2015 American Society for Reproductive Medicine guideline, 17 the optimal TSH level before IVF-ET for women with thyroid autoimmunity is less than 2.5 mIU/L and a TSH level of less than 4.0 mIU/L is preferable for women without thyroid autoimmunity undergoing IVF-ET. Subgroup analyses were performed using the RR for the stratification factors. Interactions of the intervention with the stratification factors were analyzed using binary logistic regression. Missing data were treated as missing at random and were imputed using the last-observation-carried-forward method. For the missing values (0.83%), a post hoc sensitivity analysis was conducted under the hypothesis of the worst outcomes (missing values were imputed as miscarriages) and the best outcomes (missing values were imputed as live births). No adjustment was made for multiple comparisons. Therefore, all secondary outcomes and subgroup analyses should be considered exploratory.
All statistical analyses were conducted using the statistical package SPSS, version 18.0 (SPSS Inc). Statistical significance was defined as P < .05 with 2-sided testing.
Results
Enrollment and Baseline Characteristics of Participants Scheduled for IVF-ET
Between September 6, 2012, and June 15, 2016, a total of 32 157 women referred to the Reproductive Center were screened for positive antithyroperoxidase antibody. A total of 1035 women tested positive for antithyroperoxidase antibodies in the presence or absence of positive antithyroglobulin antibodies. Four hundred seventeen women did not meet the inclusion criteria, and 18 women declined to participate in the trial (Figure) . Of the 600 eligible women (mean age, 31.6 years), 300 were randomly assigned to the levothyroxine group and 300 to the control group. The baseline characteristics were comparable between the groups except for their serum TSH levels (intentionto-treat set, Table 1 ). In addition, the values of sperm parameters including density and activity in the participant's partners did not differ between the groups. After randomization, 282 women in the intervention group and 285 women in the control group underwent their first or second fresh IVF-ET cycle (per-protocol set, eTable 1 in Supplement 2).
Protocols and Data of IVF-ET in Participants
In the intervention group, 18 women did not undergo IVF-ET, 8 of whom conceived spontaneously, 8 did not start controlled ovarian hyperstimulation, and 2 were lost to follow-up. In the control group, 15 women did not undergo IVF-ET, 6 of whom became pregnant spontaneously, 7 did not start controlled ovarian hyperstimulation, 1 had a hydatidiform mole, and 1 was lost to follow-up (Figure) . The percentage of first fresh IVF-ET cycles, distribution of protocols for controlled ovarian hyperstimulation, number of retrieved oocytes, rate of intracytoplasmic sperm injection, number of good-quality embryos, and number of transferred embryos did not significantly differ between groups ( Table 2 ; and eTable 2 in Supplement 2).
Compliance and Dosage of Levothyroxine Intervention
All the women in the intervention group took the medication as planned, of whom 3 discontinued medication due to their TSH level decreasing to less than 0.01 mIU/L with normal free thyroxine and free triiodothyronine levels (all delivered at term). In the control group, 8 women started levothyroxine treatment after controlled ovarian hyperstimulation (1 biochemical pregnancy only, 2 miscarriages, 2 preterm live births, and 3 delivered at term), and 2 women took levothyroxine after spontaneous pregnancies (both delivered at term).
In the intervention group, the mean (SD) dose of levothyroxine at the beginning of controlled ovarian hyperstimulation was 30.1 (12. 
Outcomes of the Participants
The intention-to-treat analysis showed that the miscarriage rate in the intervention group was 10.3% (11 of 107) and was 10.6% (12 of 113) in the control group for an absolute RD of −0.34% (95% CI, −8.65% to 8.12%) over the 4.5-year study period. The clinical intrauterine pregnancy rates were 35.7% (107 of 300) for the intervention group and 37.7% (113 of 300) for the control group, for an absolute RD of −2.00% (95% CI, −9.65% to 5.69%); the twin pregnancy rates, 36.4% (39 of 107) and 28.3% (32 of 113) for an absolute RD of 8.13% (95% CI, −4.19% to 20.18%); live-birth rates, 31.7% (95/300) and 32.3% (97/300) for an absolute RD of −0.67% (95% CI, −8.09% to 6.77%). Among the women who had a live birth, preterm delivery rates were 22.1% (21 of 95) in the intervention group and 19.6% (19 of 97) in the control group for an absolute RD of 2.52% (95% CI, −8.98% to 13.99%; Table 3 ).
The post hoc per-protocol analysis was consistent with the intention-to-treat analysis (eTable 3 in Supplement 2). Moreover, sensitivity analyses for the missing values in both intention-to-treat and per-protocol sets were concordant (eTable 4 and eTable 5 in Supplement 2).
To detect other clinical parameters that may affect pregnancy outcomes, post hoc subgroup analysis of miscarriage, clinical intrauterine pregnancy, and live-birth outcomes were performed for women with IVF-ET cycles. Effects of TSH level on IVF-ET outcomes were analyzed in the subgroup analysis.
No significant interaction was found. Specifically, there was no interaction effect between the intervention and the stratified factors, such as TSH, antithyroperoxidase antibody, a After controlled ovarian hyperstimulation, 2 women in the control group had no oocyte for fertilization in the intervention group, and 2 women in the control group had no oocyte and 2 men had no sperm for fertilization.
b The embryos were evaluated on the third day after fertilization. Good-quality embryos were all developed from 2 pronuclei zygotes and met the following criteria:
(1) had more than 5 blastomeres; (2) size difference was less than 20%; and (3) fragmentation was less than 50%.
c Fisher exact test. 
Discussion
This randomized clinical trial investigating whether levothyroxine treatment affected pregnancy outcomes among women undergoing IVF-ET who had normal thyroid function and had tested positive for antithyroperoxidase antibody found that levothyroxine treatment did not reduce miscarriage rate or improve the live-birth rate compared with usual care. Stagnaro-Green and Glinoer 18 first reported that women with thyroid autoimmunity had a 2-fold increased risk of miscarriage (17% vs 8.4%, P = .01) and that the risk of miscarriage was not associated with maternal age, thyroid hormone levels, or previous obstetrical history in a prospective cohort study. Since then, many small-scale clinical studies have indicated that the miscarriage rate and preterm delivery rate among women with thyroid autoimmunity who had conceived naturally were significantly higher than those without thyroid autoimmunity. 19, 20 An adverse association between presence of thyroid autoantibodies and IVF-ET outcomes was first described by Geva et al, 21 but subsequent studies on IVF-ET outcomes provided contradictory results. 22-24 A recent meta-analysis 25 investigating the effect of thyroid autoantibodies on IVF-ET outcomes showed that presence of thyroid autoantibodies did not affect fertilization, implantation, or clinical pregnancy rate but may have a detrimental effect on the course of a pregnancy, determining an increased miscarriage rate and a decreased live-birth rate. However, the authors also pointed out that age and TSH level were not comparable between the groups, suggesting that further evidence is warranted prior to drawing inferences on causality.
Given that pregnancy may trigger progression to subclinical or overt hypothyroidism in women who otherwise have normal thyroid function but have tested positive for thyroid autoantibodies, 26 it was hypothesized that they would benefit from levothyroxine treatment in pregnancy. In a retrospective cohort study assessing the effectiveness of levothyroxine intervention initiated before starting controlled ovarian hyperstimulation among this population of women undergoing IVF-ET, a fixed dose of 50 μg/d of levothyroxine treatment alone did not reduce the miscarriage rate. 27 A pooled analysis of 3 randomized clinical trials evaluating the effectiveness of levothyroxine treatment on pregnancy outcomes among women with thyroid autoimmunity but had normal thyroid function who were undergoing IVF-ET showed that levothyroxine treatment was associated with a significant decrease in the miscarriage rate (RR, 0.45; 95% CI, 0.24-0.82) and an increase in the live-delivery rate (RR, 2.76; 95% CI, 1.20-6.44). However, these 3 trials were heterogeneous in many aspects and the sample size of each trial was rather small, which may weaken the quality of the evidence. 28 Therefore, the 2011
American Thyroid Association 29 and the 2012 Endocrine Society 30 guidelines for the diagnosis and treatment of thyroid disease during pregnancy both declared that there was insufficient evidence to recommend for or against treating women with normal thyroid function experiencing sporadic or recurrent miscarriage or undergoing IVF-ET with levothyroxine. Furthermore, the American Thyroid Association took a similar position in its 2017 guideline.
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Our study showed that levothyroxine treatment did not affect pregnancy outcomes among participating women. Because the sample size of this trial was much larger, the finding that a levothyroxine supplement was not associated with any beneficial effect on pregnancy outcomes regardless of miscarriage rate, clinical pregnancy rate, or live-birth rate among women undergoing IVF-ET who tested positive for antithyroperoxidase antibody but had normal thyroid function was robust. In 2016, Negro et al 31 reported that the levothyroxine intervention showed no beneficial effect on the rate of miscarriage or preterm delivery in unselected pregnancy of women with normal thyroid function who tested positive for thyroid autoantibodies and whose TSH values were less than 2.5 mIU/L. Whether TSH levels of 2.5 mIU/L or higher affects IVF-ET outcomes is of great concern for obstetricians and endocrinologists. To address those concerns, we performed a subgroup analysis to identify specific subgroups of women who might benefit from levothyroxine treatment. We used TSH concentrations of 2.5 mIU/L or higher and 4.0 mIU/L or higher as cut points based on the recommendation of the 2015 American Society for Reproductive Medicine guideline. 17 However, no beneficial effect in any specific subgroups was found. Our finding is congruent with the observations from 2 recent cohort studies on the association of TSH levels with IVF-ET outcomes. One cohort study that evaluated the optimal TSH range before IVF-ET did not find any detrimental effect of TSH levels ranging between 2.5 mIU/L and 4.2 mIU/L on pregnancy outcomes compared with levels that were less than 2.5 mIU/L.
32
The other study showed that the miscarriage rate was not associated with TSH levels in women with intact thyroid function undergoing IVF-ET. 33 Moreover, a large observational study showed that levothyroxine treatment did not decrease pregnancy loss in women with baseline TSH levels ranging between 2.5 mIU/L and 4.1 mIU/L in unselected pregnancy.
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Those data are consistent with the results of this trial. Our study has several strengths. First, to our knowledge, it represents the largest sample of participants to assess the effectiveness of levothyroxine treatment for this population. Second, only participants in their first-or second-fresh IVF-ET cycle were included, thus excluding an effect of multiple IVF-ET failure cycles on the titer of antithyroperoxidase antibody. 35 Third, our trial excluded women with recurrent miscarriage or other autoimmune diseases, which frequently are comorbidities among women with thyroid autoimmunity, thus excluding confounding effects that might be associated with adverse pregnancy outcomes.
36,37
Limitations Our study has several limitations. First, this study was an openlabel trial without placebo. In an open-label study, the unblinded treatment and assessment might theoretically influence reporting or measurement of the outcomes, thus introducing bias. However, this study was an independent investigator-initiated trial and the primary outcome of this trial was miscarriage after IVF-ET. It is an objective event that can hardly be biased by the nonblinding assessment. The adherence rate of participants was high. Only 10 of 300 women in the control group received levothyroxine treatment, and 3 of 300 in the intervention group ceased the treatment. In addition, given that the placebo effect is more important for a study with positive results than a study with negative results like this trial, it was acceptable to consider that the open-label design without placebo would not undermine the results of this trial substantially. Second, this study was a single-center randomized clinical trial. Caution should be used when extending this result to other patient populations. However, a single-center trial might be helpful in several aspects: the quality of IVF-ET procedure and laboratory examination was better controlled in a single center than multiple centers; the Center of Reproductive Medicine of Peking University Third Hospital performs more than 10 000 cycles of IVF-ET per year, providing us with enough potential participants for this trial; moreover, the participants were from all over the country, so the population in this trial was representative. Third, despite randomization, the TSH distribution was skewed with a little higher median value in the intervention group. However, stratified analysis by TSH level did not change the conclusion. Fourth, although controlled ovarian hyperstimulation protocols were nonuniform, the various protocols were distributed similarly between the groups. Fifth, the levothyroxine dosage was relatively low, which might weaken the effect of levothyroxine. In addition, the miscarriage rate was lower than expected, which reduced the power of the study. This lower miscarriage rate might be explained by the fact that women with known comorbidities related to miscarriage-including recurrent miscarriage, known history of autoimmune diseases or presence of their markers (such as antinuclear antibody, anticardiolipin antibody and lupus anticoagulants)-were excluded from this trial. Therefore, our findings might not be applicable to women at increased risk of miscarriage.
Although our trial showed that levothyroxine treatment did not benefit this population, 2 other ongoing trials are investigating its effect on other populations. The TABLET trial (ISRCTN 15948785; http://www.birmingham.ac.uk/research /activity/mds/trials/bctu/trials/womens/tablet/index.aspx) investigates the effect of daily administration of 50 μg of thyroxine to women with intact thyroid function who tested positive for thyroidperoxidase vs placebo on live-birth outcomes. The T 4 -LIFE study (NTR 3364) investigates the benefits of levothyroxine treatment of women with intact thyroid function who have experienced recurrent miscarriages and have tested positive for the antithyroperoxidase antibody. 38 Nevertheless, it should be worth noting that the 2 ongoing trials did not focus on women undergoing infertility treatments.
Conclusions
Among women in China who had intact thyroid function and tested positive for anti-thyroperoxidase antibodies and were undergoing IVF-ET, treatment with levothyroxine, compared with no levothyroxine treatment, did not reduce miscarriage rates or increase live-birth rates. 
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The Effect of Levothyroxine Treatment on Pregnancy Outcomes of In Vitro
Fertilization in Euthyroid Women with Thyroid Autoimmunity Protocol summary Objectives:
To investigate whether the levothyroxine (L-T 4 ) treatment improves pregnancy outcomes of in vitro fertilization (IVF) in euthyroid women with thyroid autoimmunity (TAI).
Design:
A single center, open label, randomized and controlled trial
Participants:
Six hundred euthyroid women with TAI are randomized to either L-T 4 treatment or usual care with the ratio of 1:1. Six hundred euthyroid infertile women with TAI are randomized to either L-T 4 treatment (intervention group, n=300) or usual care (control group, n=300).
Intervention group: L-T 4 treatment initiates at least two weeks before the controlled ovary hyperstimulation (COH).
The dosage is adjusted to maintain the level of TSH within specific ranges (within 12 weeks of gestation, 0.1-2.5 mIU/L;
12-24 weeks of gestation, 0.2-3.0 mIU/L; after 24 weeks of gestation, 0.3-3.0 mIU/L). The medication is discontinued if the participants do not achieve pregnancy.
Control group: They receive no intervention. Their thyroid functions are monitored as same as the subjects in intervention group.
Primary and secondary outcomes
The primary outcome was miscarriage rate.
The secondary outcomes were clinical pregnancy rate and live birth rate.
Medication
Levothyroxine Sodium Tablets (50 g/tablet), aluminium foil package (Merck Serono Company)
Statistical analysis:
Double-entry is applied by using the EPI 3.0 software. Analyses are performed after the data was checked by inspectors. The main outcomes are compared between two groups using chi-square test and relative risk with 95% CI.
Comparison between groups was performed with independent sample t test or Mann-Whitney test, or Pearson chi-square test or fisher's exact test as appropriate.
All Statistical analyses were done using the statistical package SPSS, version 18.0 (SPSS Inc., Chicago, IL). Statistical significance was defined as P < 0.05 with two tails.
Plan of follow-ups: The Effect of Levothyroxine Treatment on Pregnancy Outcomes of In Vitro Fertilization in Euthyroid Women with Thyroid Autoimmunity
Background TAI and reproductive health
Thyroid autoimmunity (TAI) is defined as the presence of thyroid peroxidase antibody and/or thyroglobulin antibody.
It is the most common cause of hypothyroidism among women of childbearing age, with a prevalence of 8-15% (1).
Thyroid hormone plays an important role in the fecundity of female, involving the regulation of oocyte maturation and embryonic development. The lack of thyroxine in pregnant women could lead to severely impaired development of the nervous system of fetus. Especially in early gestation, thyroxine is not able to be synthesized by the fetus and has to be supplied by the mother completely (2). Therefore, the optimal supply of thyroxine is an important aspect of eugenics.
To adapt to the physiological changes during gestation, the function of mother's thyroid gland is remarkably altered.
The characteristics in gestation include increased estrogen, thyroid binding globin (TBG), Total triiodothyronine (TT 3 ) and total thyroxine (TT 4 ) levels. The rapid elevation of human chorionic gonadotropin (hCG) in the early trimester plays a similar role to thyroid stimulating hormone (TSH), stimulating the secretion of thyroxine, thus leading to the increase of TT 4 and free thyroxine (FT 4 ) levels and decrease of TSH level. In addition, the increased iodine clearance rate from the mother kidney during pregnancy results in a higher demand of iodine. In conclusion, the pregnant women are at the status of physiological hyperthyroidism (3) . Therefore pregnant women with TAI, whose thyroid reserve is possibly impaired, are at a risk of hypothyroidism during pregnancy (4).
It is well documented that hypothyroidism during pregnancy would increase the risk of adverse outcomes of mother and fetus, including preeclampsia, malposition, miscarriage, fetal abnormalities, and nervous system abnormalities especially. Nowadays, it is well accepted that levothyroxine (L-T 4 ) treatment for overt hypothyroidism or subclinical hypothyroidism during pregnancy definitely improves the pregnancy outcomes (5).
TAI and in vitro fertilization (IVF)
It was reported that the prevalence of TAI in women with infertility or recurrent miscarriage was higher than that in age-matched multipara (6, 7) . Infertile women with polycystic ovary syndrome (PCOS), endometriosis and recurrent miscarriage tend to be complicated with TAI, of which the underlying mechanism remains unknown.
Previous data of our Reproductive Center shows that the prevalence of TAI in infertile women is about 11.1% (N=9541), and the positive rate of TPOAb increased with age (7% in the group aged less than 25 years and 14% in the group older than 40 years).
The number of women conceiving through assisted reproductive technology (ART) is increasing rapidly year by year.
IVF is a type of ART in which eggs (ova) are removed from a woman's ovary and fertilized by sperm outside the body using a laboratory procedure, and then the fertilized egg (embryo) is transplanted to the woman's uterus. Different from spontaneous conception, most infertile women have to go through controlled ovarian hyperstimulation (COH) during the process of IVF. The use of high dose of gonadotropin inevitably results in dramatic increase of estrogen level within two weeks, comparable to the level in the secondary trimester. The trigger of hCG before oocytes retrieval raises the demand of thyroxine as conceiving. Therefore, female TAI individuals with impaired thyroid reserve are prone to suffer from thyroid insufficiency because of the dramatic changes of hormones during pregnancy (8) . Besides, the prevalence of TAI was higher among women with recurrent IVF failure, the possible explanation of which is that the repeated COH disturbs the regulation of the immune system and increase the risk of TAI (9).
As mentioned above, it is recommended to initiate replacement therapy before and during pregnancy in women with hypothyroidism and subclinical hypothyroidism. However, for euthyroid women with TAI, it is currently unclear whether levothyroxine treatment improves the outcomes of IVF as the relevant studies were limited and had small sample sizes with inconsistent results. A meta-analysis in women with TAI undergoing their first cycle of IVF shows that the pregnancy rate is similar to that of the control, but the miscarriage rate is increased (10) . The same conclusion is made in the analysis of 299 women with TAI undergoing their first cycle of IVF in our Center (similar pregnancy rates, miscarriage rate in the TAI group increased by 2 folds).
Owing to reported studies were limited and had small sample sizes (11, 12) 
Methods and Design
Objective:
To investigate whether the L-T 4 treatment improves pregnancy outcomes of IVF in euthyroid women with TAI.
Design:
This is a single center, open labeled, randomized and controlled trial. From an ethical point of view, blinding method is inappropriate for this specific population.
Participants:
Beginning from June 2012, all infertile women preparing to receive IVF treatment in Peking University Third hospital
Reproductive Health Center are candidates for screening. They will be invited to provide a blood sample for the assay of thyroid antibody and thyroid function. All euthyroid women with TAI are selected as potential participants. From them total 600 eligible participants will enter this study after careful inquiry for the past history and laboratory assay.
Follow-up would be continued until the end of the last pregnancy. According to our pilot study, up to 150-180 participants could be screened out each year. The duration of recruitment is assumed to be 4-5 years.
Six hundred euthyroid women with TPOAb positivity will be randomized to the intervention group and control group.
Randomization was performed by an independent data manager, with a computer developed randomization sequence with the ratio of 1:1.
Inclusion criteria: 
8) Psychiatric disorders
Withdrawal criteria:
1) Participants are able to voluntarily withdraw from the study at any moment.
2) The researchers consider that some participants should be withdrawn from the study based on medical points of view.
3) Participants who had withdrawn already cannot be reincluded into the study again.
Research procedure
The participants are randomized to either L-T 4 treatment (intervention group, n=300) or usual care (control group, n=300). L-T 4 treatment initiates at least 2 weeks before COH with dose of 12.5-50 g/day in intervention group. The dose of L-T 4 was determined according to the weight and thyroid function of each participant. Medication was continued if the participants achieved clinical pregnancy, and participants will be told to adjust the dose of L-T 4 according to their TSH level during pregnancy in local hospitals. Women in the control group do not take L-T 4 .
Dosage and adjustment
The dosage is determined according to the weight and thyroid function of each participant For individuals with TSH level ≥ 2.5 mIU/L, the starting dose was 50 g/day, while those with TSH < 2.5 mIU/L started at 25 g/day. For participants with body weight less than 50kg, the starting dose was decreased with 50%. . The medication is taken at least 30 minutes before breakfast. The thyroid function will be tested on the day of hCG injection, day 14 and day 30 after embryo transplantation (ET). The medication continues if the participants achieve clinical pregnancy, and they will be told to adjust the dosage according to their TSH level tested in local hospital during pregnancy. Telephone follow-ups were performed every 3 months after successful ET, recording the pregnancy outcomes and medication. We followed each participant after their fresh IVF cycle. In the first trimester, the level of TSH should be maintained between 0.1-2.5 mIU/L. In the second and third trimester, the thyroid function should be tested, and the level of TSH should be maintained between 0.2-3.0 mIU/L and 0.3-3.0 mIU/L respectively until parturition (13) . The references for dosage adjustment are listed as followed: In the control group, thyroid function monitoring is no longer required from day 30 after ET, while regular telephone follow-ups are continued. In the control group, if the level of TSH > 4.78 mIU/L, the L-T 4 treatment has to initiated and recorded.
Medication dispensing
L-T 4 will be prescribed by physicians and dispensed to the participants in intervention group. The remaining drug will not be recovered.
Plan of follow-up
The plan of follow-up is listed in Table 1 . Table 1 .The plan of follow-up
Data collection
Demographic characteristics, including height, weight, BMI, blood pressure, heart rate, causes of infertility and concomitant medications are all collected at the first visit.
Thyroid function and the titration of thyroid auto-antibodies are assayed at the laboratory of Peking University Third
Hospital.
All the adverse events need to be recorded.
As to the safety of L-T 4 treatment during pregnancy, there is no clear or consistent evidence of serious adverse effect of L-T 4 on mothers or babies. No fetus toxicity or teratogenicity is reported. The medication in pregnancy women is recommended by guidelines. The safety of medication is related to the L-T 4 dosage. Thyroid function monitoring is the major approach to determine optimal dosage. Overdose of L-T 4 possibly leads to hyperthyroidism, which should be paid attention to and recorded.
All the visits will be recorded in case report forms (CRFs).
Outcomes:
The primary outcome was miscarriage rate. Miscarriage is defined as a pregnancy that lasted < 28 weeks prior to termination. Miscarriage is classified as early miscarriage (termination within the first 12 weeks of gestation), mid-term miscarriage (termination of pregnancy within 12-20 weeks of gestation), and late miscarriage (miscarriage within 20-28 weeks of gestation).
Secondary outcomes were clinical pregnancy rate and live birth rate. Clinical pregnancy is defined as fetal cardiac activity seen by sonography observation at day 30 after the ET procedure. Live birth is defined as a delivery of a living fetus (or living fetuses) beyond 28 weeks of gestation. Multifetal pregnancy is defined as the presence of two fetal pools with cardiac activity.
For the evaluation of IVF, we compare the number of retrieved oocytes, number of superior embryos defined as the embryo having 6-10 cleavage balls after ovum collection and 2 grades above between two groups.
Sample size
Previous meta-analysis showed that the miscarriage rate among TAI group was about 30% and L-T 4 intervention may reduce the risk of miscarriage by 50% (14) . We hypothesized that supplement o f LT 4 may reduce the risk of miscarriage by 50%. To detect a 50% decrease in miscarriage rate (from 30% to 15%) with error of 0.05 and error of 0.2, 120
clinical pregnancies were needed. Since the clinical pregnancy rate based on retrospective data in our center was about 42%, we needed 285 fresh cycles for each arm. Anticipating a 5% drop-out rate, the total number of women required for randomization was 300 for per arm ( 
Data management
Data collection
The investigators are responsible for recording the complete data of the participants in the CRFs in time. After checked by the monitor, the signed CRFs will be handed to the administrator of data.
Double-entry and double comparison are applied. Any discrepancy needs to be reported to the monitors, and the investigators should answer for it. All questions and replies should be recorded in a query form and saved.
Data verification and management
After all data is confirmed, the administrator should complete a report about the completion of the study (including a drop-off list), check the inclusion/exclusion criteria, integrity, logical consistency, outlier data, time window, accompanied medication and adverse events.
At the audit meeting, the main investigators, monitors, data administrators and statisticians will make resolutions about the informed consents and query forms. After audit meeting, a review of the meeting is documented and the database should be locked.
Data archive
CRFs will be checked and saved in numerical order with search catalogs. Electronic data, including the database, inspection procedure, analysis program, results of analysis, codebook and description files, etc., should be classified and stored. Multiple backups should be saved on different disks or recording media. All original files should be stored within the stipulated time limit.
Data analysis
Intention-to-treat principle (ITT) was applied in our analysis. Data were expressed as mean ± S.D. or n (%). We compared the primary and secondary outcomes as absolute differences and by calculating relative risks with 95%
confidence interval compared to the control group.
Safety evaluation
Levothyroxine is produced by the company Merck Drugs & Biotechnology. It's widely used to treat hypothyroidism and other related disorders. There are substantial evidence shows that Levothyroxine is not expected to harm a fetus (no toxic effect on the fetus and would not cause deformity). Harm to the fecundity of male and female was not documented.
For women diagnosed with hypothyroidism and subclinical hypothyroidism, levothyroxine is recommended during their gestation, to reduce the incidence of adverse pregnancy outcomes (14) . Substitutive dose of levothyroxine is safe for pregnant women. Pregnancy outcomes are the main outcome measures in our study, and all the adverse events will be determined if they are correlated with the medication and then documented.
Protection of rights and interests of participants and informed consent
Only after the permission of the ethic committee this study can initiate.
The decisions of the ethics committee, including approval, approval after modifications, disapproval, termination or suspension of the approved trial, must be accepted. It's the responsibility of the involved physicians to provide the patient with details of the clinical trial, including the aims and property of the study, their probable profit and risks, other available therapeutic options, and the rights and obligations of the participants that in accordance with the provisions of the Helsinki declaration, etc.
When the participants are fully informed and agree to join in the study, they sign the informed consent and we are allowed to conduct the trial on individuals.
Quality control
The involved physicians should be trained before the trial and remain relatively fixed. The participants are requested to have a visit on time as programmed. For patients who do not visit on time, the investigators should follow up. It's the responsibility of the investigators to fully inform the patients and their relatives the meaning of the trial, and to promote the compliance of the patients and insure medication taking on time.
Premature termination of the study
The trial must be terminated in time if serious safety problem presented.
The trial must be terminated if the intervention shows very poor treatment effect, or even no effect.
The trial must be terminated if major errors are presented in the clinical trial, or serious deviations are found in the implementation of the trial resulting in a difficulty in evaluating the effect of the medication. After controlled ovarian hyperstimulation, 2 women had no oocyte for fertilization in the intervention group, and 2 women in the control group had no oocyte and 2 men had no sperm for fertilization. The embryos were evaluated on the third day after fertilization. Good-quality embryos were all developed from 2 pronuclei zygotes; and met the following criteria: (1) the number of blastomeres more than 5; (2) size difference less than 20%; (3) fragmentation less than 50%. The per-protocol analysis was defined as all individuals undergoing in vitro fertilization-embryo transfer.
b
The cut point of baseline thyroid stimulating hormone level in subgroup analyses was defined according to the 2015 ASRM guideline. c After controlled ovarian hyperstimulation, two had no oocyte for fertilization in the intervention group, and two had no oocyte and two had no sperm for fertilization in the control group.
Subgroups
No The cut point of baseline thyroid stimulating hormone level in subgroup analyses was defined according to the 2015 ASRM guideline. c After controlled ovarian hyperstimulation, two had no oocyte for fertilization in the intervention group, and two had no oocyte and two had no sperm for fertilization in the control group. 
